Both in my role as Chairman of the Federal Association of the Pharmaceutical Industry (BPI) and as Managing Director of Desitin Arzneimittel GmbH, it is very important to me that the discussion that has been simmering for years is brought to a sensible conclusion and that the current label fraud does not remain the same.
Inhalable anti-asthmatics, dermatics and sustained-release opioids are examples of product groups from BPI member companies that may not be replaced without specific medical reasons and whose uncontrolled substitution for cost reasons, in addition to the negative consequences for the patient, will ultimately lead to cost increases instead of savings.
Findings already available and to be generated from health services research should be increasingly incorporated into decision-making.
But especially for Desitin's indication area of epilepsy with its highly individual patient-related therapy and numerous active ingredients with a narrow therapeutic range (carbamazepine, valproic acid, phenytoin, primidone, phenobarbital, ...) are also after long, tough negotiations by the pharmacist and health insurance representative as well as in the aftermath of one now almost two years of “breeding time”
... <<